Travere Therapeutics (NASDAQ:TVTX) saw a 25.3% rise due to strong earnings. It swung to a net income of $25.7 million in Q3 from a loss last year. Revenues grew by 162%, driven by Filspari sales.
Read MoreDid you find this insightful?
Bad
Just Okay
Amazing